C5 and COVID-19: Earlier, in a substudy of an exploratory, open-label phase 2 trial as part of PANAMO, we showed that vilobelimab suppressed C5a levels in 10 severely ill COVID-19 patients after a single infusion, as compared to 12 controls, which was maintained for at least eight days [8].